Employees: 334
Size Evolus (EOLS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $468M, the 2718th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.07 on 18 Nov 2026.
Performance Over six months the shares gained 7.3%, against -9.3% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 13.9% over the last twelve months (peer median +12.5%); the operating margin is -5.0% (peer median 7.6%).
Valuation It trades at 28.5× forward earnings against a peer median of 24.0× (2nd most expensive of 5).
Capital Return on invested capital runs 25.2 points below its cost of capital (10.3% WACC).
Short interest Short interest is 9.1% of the free float (30 Oct 2026).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $325M | $297M | $266M | $202M | $149M |
| Revenue growth | — | +12% | +32% | +36% | — |
| Gross profit | $210M | $193M | $180M | $135M | $89.0M |
| EBITDA | -$5.28M | -$28.9M | -$21.2M | -$30.2M | -$55.1M |
| Net income | -$31.1M | -$51.6M | -$50.4M | -$61.7M | -$74.4M |
| Free cash flow | -$4.91M | -$45.7M | -$19.5M | -$34.5M | -$86.5M |
| Capital expenditure | $6.17M | $8.45M | $4.82M | $1.63M | $2.94M |
| Total debt | $166M | $155M | $130M | $127M | $74.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EOLS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.1% | -2.1% | 10th lowest of 21 |
| 6-month return | +7.3% | -9.3% | 7th highest of 20 |
| Distance from 52-week high | -24.1% | -39.2% | 6th highest of 21 |
| Revenue growth (TTM) | +13.9% | +12.5% | 9th highest of 20 |
| Operating margin | -5.0% | 7.6% | 9th lowest of 19 |
| Forward P/E | 28.5× | 24.0× | 2nd most expensive of 5 |
| ROIC minus cost of capital | -25.2 pp | -3.3 pp | 4th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 28.5× | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | n/a | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 24.9× | 24.8% | +126.7% |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | n/a | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | n/a | 44.1% | +1.0% |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | n/a | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | n/a | -3.8% | +0.7% |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | n/a | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 42.2× | n/a | n/a |
| Assembly Biosciences ASMB | United States | $458M | -15% | +80% | -32% | n/a | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | n/a | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | n/a | -4.7% | +105.3% |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | n/a | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | n/a | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $452M | +48% | +17% | 14% | n/a | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 18.2× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | n/a | 3.3% | -1.1% |
| Pulike Biological Engineering 603566.SS | China | $449M | -21% | -9% | 5% | 23.2× | 4.5% | +3.3% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | n/a | 8.9% | +9.1% |